June 1958

Fate of Human Aortic Homografts Ten, Twenty-Four, and Twenty-Seven Months After Transplantation

Author Affiliations

Houston, Texas
From the Cardiovascular Surgery Section, Department of Surgery, Hermann Hospital; the Surgical Service, Southern Pacific Hospital, and the Department of Pathology, Hermann Hospital and Southern Pacific Hospital.; Attending, Cardiovascular Surgery Section, Department of Surgery, Hermann Hospital; Assistant to the Chief Surgeon, Southern Pacific Hospital (Dr. Denman). Chief, Department of Pathology, Hermann and Southern Pacific Hospitals (Dr. Brown). Resident, Department of Pathology, Hermann Hospital (Dr. Skinner). Formerly Chief Resident, Surgery, Hermann Hospital; Resident, Thoracic Surgery, Hahnemann Hospital, Philadelphia (Dr. Fitch). Co-Chief Resident, Surgery, Hermann Hospital (Dr. Glass).

AMA Arch Surg. 1958;76(6):944-950. doi:10.1001/archsurg.1958.01280240102016

The use of aortic homografts in the treatment of aneurysmal or occlusive aortic disease is well established.5,7,9,12,14,17 Experimental studies1,2,11,16,18,19,21-23 concerning the long-term fate of arterial homografts in animals have shown a definite pattern of response—namely, the homograft serves well as an inert, nonviable blood-carrying conduit while undergoing a gradual process of degeneration and partial replacement by an invasive and circumferential growth of fibrous connective tissue from the host.

Observations concerning the fate of human aortic homografts have been few. Gwathmey13 has reported the occurrence of aneurysm formation due to subacute bacterial infection in a human aortic homograft five months after transplantation, and others9 have expressed concern regarding the occurrence of late degenerative changes which have resulted in various complications. De Bakey,6 in a study of 10 aortic homografts from 1 to 360 days after transplantation, observed that the human aortic homograft loses its structural identity

First Page Preview View Large
First page PDF preview
First page PDF preview